OP76 Direct Costs Associated With HER2+ Breast Cancer Care In A Colombian Healthcare Institution: A Real-World-Evidence Study
Manuel González, Sandra Arauchan, Sergio Beltran, José Lobatón, Danis Rojas, Javier Ospina, Daniel Samacá · 2025
Read OP76 Direct Costs Associated With HER2+ Breast Cancer Care In A Colombian Healthcare Institution: A Real-World-Evidence Study by Manuel González, Sandra Arauchan, Sergio Beltran, José Lobatón, Danis Rojas, Javier Ospina, Daniel Samacá (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768812.txt.
Description
Manuel González and co-authors count in 2025 what it costs a Colombian health center to care for women with a fast-growing type of breast cancer. Money limits can squeeze cancer care, so knowing where the costs sit helps planning. The team read the records of 289 women treated between 2018 and 2022 and sorted each cost by the stage of the disease at the start.
Total care for the group came to just over thirteen million US dollars. Drugs made up 83 percent of that, with procedures a distant second. Average cost per patient climbed steeply with stage. It ran about five times the earliest stage for early cancer, over seven times for locally advanced disease, and nearly fourteen times for spread cancer. The authors argue the figures strengthen the case for finding this cancer early, on money grounds alone.
Catalog record
| CREATOR | Manuel González, Sandra Arauchan, Sergio Beltran, José Lobatón, Danis Rojas, Javier Ospina, Daniel Samacá |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |